Pictorial essay: incidental findings on 18F-Fluciclovine PET/CT scan
Authors (first, second and last of 6)

Reviews in Nuclear Medicine and Molecular Imaging
This journal covers clinical practice and translational research and clinical applications of approved and experimental radiopharmaceuticals for diagnostic and therapeutic purposes, benefiting a wide readership of nuclear medicine and allied professionals.
The journal complies with ethical guidelines, authors have to declare any Conflict of Interest in detail. Authors must also state that they conformed with the Helsinki Declaration of 1975 concerning Human and Animal Rights, and that they followed out policy concerning Informed Consent. Further details about the ethical policies are available under "Ethics & Disclosure".
This is the journal of the Italian Association of Nuclear Medicine (AIMN). AIMN members have free access to the journal.
Please find here the latest articles published on COVID-19.
With great pleasure we announce the first impact factor of CATI.
The impact factor 2019 is 2,506, found on rank 58 out of 133 in the category "Radiology, Nuclear Medicine & Medical Imaging".
Thank you everybody for your support to achieve this milestone.
This is to announce that
Laura EVANGELISTA, MD PhD
Nuclear Medicine Unit - Department of Medicine DIMED, University of Padua, Padua, Italy
will be the Editor-in-Chief of Clinical and Translational Imaging
As a result of the significant disruption that is being caused by the COVID-19 pandemic we are very aware that many researchers will have difficulty in meeting the timelines associated with our peer review process during normal times. Please do let us know if you need additional time. Our systems will continue to remind you of the original timelines but we intend to be highly flexible at this time.
© Italian Association of Nuclear Medicine and Molecular Imaging